Abstract |
Intravenous immunoglobulin ( IVIG) is a potential therapy for chronic inflammatory demyelinating polyneuropathy ( CIDP). To investigate the efficacy and safety of the IVIG IgPro10 ( Privigen) for treatment of CIDP, results from Privigen Impact on Mobility and Autonomy (PRIMA), a prospective, open-label, single-arm study of IVIG in immunoglobulin (Ig)-naïve or IVIG pre-treated subjects (NCT01184846, n = 28) and Polyneuropathy And Treatment with Hizentra (PATH), a double-blind, randomized study including an open-label, single-arm IVIG phase in IVIG pre-treated subjects (NCT01545076, IVIG restabilization phase n = 207) were analyzed separately and together (n = 235). Efficacy assessments included change in adjusted inflammatory neuropathy cause and treatment (INCAT) score, grip strength and Medical Research Council (MRC) sum score. Adverse drug reactions (ADRs) and ADRs/infusion were recorded. Adjusted INCAT response rate was 60.7% in all PRIMA subjects at Week 25 (76.9% in IVIG pre-treated subjects) and 72.9% in PATH. In the pooled cohort (n = 235), INCAT response rate was 71.5%; median time to INCAT improvement was 4.3 weeks. No clear demographic differences were noticed between early (responding before Week 7, n = 148) and late responders (n = 21). In the pooled cohort, median change from baseline to last observation was -1.0 (interquartile range -2.0; 0.0) point for INCAT score; +8.0 (0.0; 20.0) kPa for maximum grip strength; +3.0 (1.0; 7.0) points for MRC sum score. In the pooled cohort, 271 ADRs were reported in 105 subjects (44.7%), a rate of 0.144 ADRs per infusion. This analysis confirms the efficacy and safety of IgPro10, a recently FDA-approved IVIG for CIDP, in a population of mainly pre-treated subjects with CIDP [Correction added on 14 March 2019 after first online publication: the INCAT response rate has been corrected.].
|
Authors | Ingemar S J Merkies, Ivo N van Schaik, Jean-Marc Léger, Vera Bril, Nan van Geloven, Hans-Peter Hartung, Richard A Lewis, Gen Sobue, John-Philip Lawo, Billie L Durn, David R Cornblath, Jan L De Bleecker, Claudia Sommer, Wim Robberecht, Mika Saarela, Jerzy Kamienowski, Zbigniew Stelmasiak, Björn Tackenberg, Orell Mielke, PRIMA Trial Investigators and the PATH Study Group |
Journal | Journal of the peripheral nervous system : JPNS
(J Peripher Nerv Syst)
Vol. 24
Issue 1
Pg. 48-55
(03 2019)
ISSN: 1529-8027 [Electronic] United States |
PMID | 30672091
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © 2019 The Authors. Journal of the Peripheral Nervous System published by Wiley Periodicals, Inc. on behalf of Peripheral Nerve Society. |
Chemical References |
- Immunoglobulins, Intravenous
- Immunologic Factors
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Double-Blind Method
- Europe
- Female
- Humans
- Immunoglobulins, Intravenous
(administration & dosage, pharmacology)
- Immunologic Factors
(administration & dosage, pharmacology)
- Male
- Middle Aged
- Outcome Assessment, Health Care
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
(drug therapy)
- Prospective Studies
- Young Adult
|